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Aim The impact of rate and rhythm control strategies on outcomes in patients with atrial fibrillation (AF) remains con-
troversial. Our aims were: to report use of rate and rhythm control strategies in European patients from the
EURObservational Research Program AF General Pilot Registry. Secondly, to evaluate outcomes according to as-
signed strategies.
...........................................................................................................................................................
Methods
and results
Use of pure rate and rhythm control agents was described according to European regions. 1-year follow-up data
were reported. Among rate control strategies, beta-blockers were the most commonly used drug. Proportions of
patients assigned to rhythm control varied greatly between countries, and amiodarone was the most used rhythm
control drug. Of the original 3119 patients, 1036 (33.2%) were assigned to rate control only and 355 (11.4%) to
rhythm control only. Patients assigned to a rate control strategy were older (P< 0.0001) and more likely female
(P= 0.0266). Patients assigned to a rate control strategy had higher rates for any thrombo-embolic event
(P= 0.0245), cardiovascular death (P= 0.0437), and all-cause death (P< 0.0001). Kaplan–Meier analysis showed that
rate control strategy was associated with a higher risk for all-cause death (P< 0.001). On Cox regression analysis,
rate control strategy was independently associated with all-cause death (P= 0.0256). A propensity matched analysis
only found a trend for the association between rate control and all-cause death (P= 0.0664).
...........................................................................................................................................................
Conclusion In a European AF patients’ cohort, a pure rate control strategy was associated with a higher risk for adverse events
at 1-year follow-up, and partially adjusted analysis suggested that rate control independently increased the risk for
all-cause death. A fully adjusted propensity score matched analysis found that this association was no longer statis-
tically significant, suggesting an important role of comorbidities in determining the higher risk for all-cause death.
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Introduction
Apart from stroke prevention, another important aspect of atrial fib-
rillation (AF) management involves symptom control with the phys-
ician having to decide whether to employ a rate control, rhythm
control or a combination strategy with regard to each individual AF
patient. For the majority of patients, current European Society of
Cardiology (ESC) Guidelines suggest that rate control should be the
initial preferred management strategy, with rhythm control strategy
suggested in AF patients who remain symptomatic despite adequate
ventricular rate control.1 Moreover, rate control therapy would be
essential in the clinical management of AF patients, even in those who
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ultimately require a rhythm control strategy.2 Nonetheless, phys-
icians still frequently consider the two strategies as mutually exclusive
alternatives, despite rate control being part of rhythm control.
Whilst both rate and rhythm control strategies do improve symp-
toms, there is no conclusive evidence to demonstrate an improved
survival with either strategy.2–5 Various studies addressing the basic
issue of whether converting AF back to sinus rhythm confers mortal-
ity benefits have been on-going for over 10 years. Multiple random-
ized controlled trials (RCTs) comparing rate and rhythm control
therapies in patients with AF have not demonstrated any evidence of
superiority in terms of death or systemic embolism with either strat-
egy.3–7 Other studies have suggested contradictory results with
lower mortality shown with rhythm control compared with rate con-
trol.8–10 One issue with the large trials comparing rhythm vs. rate
control strategies has been the low rate of sinus rhythm restoration
and maintenance. In the RACE study, for example, less than 40% of
patients were in sinus rhythm at the end of the study.5
It has been suggested that an early rhythm control strategy with ei-
ther a combination of pharmacological and ablation therapies may
help in halting AF progression and improve patient outcomes. For ex-
ample, the early treatment of atrial fibrillation for stroke prevention
trial (EAST) is one such study evaluating outcomes of patients with
new onset AF managed with either rhythm control therapy or rate
control therapy.11
The EURObservational Research Programme Atrial Fibrillation
(EORP-AF) Pilot Registry was a registry sponsored by the ESC and
conducted in nine European countries to ascertain contemporary
management of AF patients amongst European cardiologists. In this
analysis, we report on the use of pure rate control management strat-
egy vs. pure rhythm control management strategy in this ‘real life’
registry. Secondly, we assessed adverse outcomes with rate or
rhythm control strategies over a 1-year follow-up.
Methods
Details on the EORP-AF study design, baseline and 1-year prospective re-
sults have been previously reported.12,13 In brief, EORP-AF was a
prospective registry of consecutive AF patients managed by cardiologists,
in nine countries (Belgium, Denmark, Netherlands, Norway, Poland,
Romania, Greece, Italy, and Portugal). All patients entered the study after
signing a written informed consent. The study was performed according
to the EU Note for Guidance on Good Clinical Practice CPMP/ECH/135/
95 and the Declaration of Helsinki.
The study enrolled both in- and outpatients accessing cardiology ser-
vices (either hospital or office-based centres) with AF as a primary or sec-
ondary diagnosis. The qualifying AF event was recorded by a 12-lead
ECG, 24 h ECG Holter, or other electrocardiographic documentation
and should have been occurred within the 12 months before enrolment.
Follow-up data were recorded 1 year after enrolment date according to
procedures previously described.13 From February 2012 to March 2013,
a total of 3119 AF patients were enrolled.
We described the use of rate and rhythm control strategies among
EORP-AF patients according to four European regions, arbitrarily defined
as follows: (i) Eastern Europe: Poland and Romania; (ii) Southern Europe:
Greece, Italy, and Portugal; (iii) Western Europe: Belgium and
Netherlands; (iv) Northern Europe: Denmark and Norway. Rate and
rhythm control strategies were defined according to ESC guidelines.1,14
To evaluate the impact of rate and rhythm control strategies on adverse
outcomes and mortality, we only considered AF patients reported by
their enrolling cardiologist as being treated with rate control only and
rhythm control only (and not both strategies). During the baseline assess-
ment, all investigators had to define the clinical management strategy, ac-
cording to the primary and/or prevalent approach. We recognize that
rate control would be used even in those AF patients that ultimately re-
quire rhythm control, those assigned to the ‘rate control only’ group
were considered as being primarily and prevalently assigned to a rate con-
trol strategy, while those considered for the ‘rhythm control only’ group
were primarily and prevalently assigned to a rhythm control strategy.
Thrombo-embolic risk was defined according to the CHA2DS2-VASc
score.15 ‘Low risk’ patients were defined as a CHA2DS2-VASc 0 in males
or 1 in females; ‘moderate risk’ was defined as male patients with a
CHA2DS2-VASc score 1; and ‘high risk’ was defined as CHA2DS2-VASc
score >_2. Bleeding risk was assessed according to the HAS-BLED
score.16
During the pre-specified 1-year follow-up, the occurrence of major ad-
verse events was recorded. Based on the study protocol, events re-
corded were as follows: cardiovascular (CV) death; all-cause death; and
any thrombo-embolic event (TE) [defined as the occurrence of any
thrombosis-related complication, i.e. stroke, transient ischemic attack
(TIA), acute coronary syndrome, coronary intervention, cardiac arrest,
peripheral or pulmonary embolism]. Follow-up data were collected ac-
cording to any centre procedures, both from follow-up visits and/or con-
sultation of medical notes.
Statistical analysis
Continuous variables were reported as mean ± SD or as median and
inter-quartile range.
Between-group comparisons were made by using a non-parametric
test (Kruskal–Wallis test).
Categorical variables were reported as percentages. Between-group
comparisons were made by using a v2 test or a Fisher’s exact test if any
expected cell count was less than five. For categorical variables with
more than two possible values, exact P-values have been estimated ac-
cording to the Monte Carlo method.
Evaluation of factors significantly associated with all-cause death used a
Cox proportional hazards analysis. All demographic variables underwent
a univariate analysis. All variables with a P-value <0.10 for the association
to all-cause death at the univariate analysis, were inserted in the stepwise
What’s new?
• The impact of rate and rhythm control strategies in atrial fibril-
lation (AF) patients on outcomes in real world cohorts is less
certain.
• AF patients managed with a rate control strategy reported
more adverse outcomes than those managed with a rhythm
control strategy.
• A rate control strategy was associated with a higher risk for
all-cause death, even if this association was found to be non
statistically significant after full adjustments with propensity
score matched analysis.
• Adequately powered randomized control trials may still be
needed, as well as large prospective ‘real world’ cohorts, to
fully assess the impact of rate and rhythm control strategies on
adverse outcomes in AF patients.
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multivariate model. Additional stepwise models were then performed in-
serting in any model a specific class of anti-atherosclerotic drugs. A
Hosmer and Lemeshow Goodness-of-Fit Test was used to verify that the
models were optimal. A two-sided P-value <0.05 was considered statis-
tically significant.
A propensity score matched (PSM) analysis was also computed.
The propensity score was estimated according to all variables con-
sidered at baseline (see Supplementary material online, Table S1), and
propensity-based matching was used to create samples of patients
treated by the therapy under study and not treated who were similar
in terms of propensity score, i.e. in terms of probability of receiving
the therapy. Unmatched observations were discarded, thus leading to
possibly non-representative samples of the original database; how-
ever, because the patients analysed were matched on many con-
founders simultaneously, such analyses are likely to provide a more
valid estimate of the treatment effect. A 1:1 matching optimal algo-
rithm without replacement was used, where all treated patients were
matched to the closest control within a range of 0.20 standard devi-
ations of the logit of the estimated propensity score. The success of
the propensity score matching was assessed by checking standardized
differences between the groups before and after matching, i.e. the ab-
solute difference in sample means divided by an estimate of the
pooled standard deviation of the variable, expressed as a percentage.
Balancing was considered as successful, if the standardized differences
were less than 10% for variables used for propensity score develop-
ment. All analyses were performed using SAS statistical software ver-
sion 9.3 (SAS Institute, Inc., Cary, NC, USA).
Results
A total of 3119 patients were enrolled, with the majority of patients
recruited from Eastern (n = 1306; 41.9%) and Southern Europe (n
= 1044; 33.5%), while only 444 (14.2%) and 325 (10.4%) patients
were enrolled, respectively, in Northern and Western Europe. In
terms of baseline characteristics, the percentage of patients with par-
oxysmal AF was higher in Northern Europe (46.7%) compared with
the other three regions (23.6%, 22.2%, and 25.6%, respectively, in
Eastern, Southern, and Western Europe).
Across the four regions, beta-blockers were the most commonly
used rate control agents, followed by digoxin (Table 1). The propor-
tion of patients with inadequate rate control (defined as a heart
rate <50 beats per minute (bpm) or > 110 bpm) ranged between
20% and 30% of patients across the four regions (Table 2). In particu-
lar, patients with inadequate rate control are more likely to be non-
(or slightly) symptomatic (EHRA I or EHRA II) in three out of four
regions (Table 2). Conversely, patients from Eastern Europe with in-
adequate rate control are more symptomatic (61.6% EHRA III or IV).
There was a wide range amongst the nine European countries in
the percentage of AF patients being treated with rhythm control
agents. Only 25.9% of patients were prescribed with antiarrhythmic
drugs in Norway, but the percentage progressively increased in Italy
(33.1%), Poland (43.4%), Netherlands (46.5%), and Romania (50.6%).
More than half of patients were treated with antiarrhythmic drugs in
Portugal (54.3%), Belgium (63.2%), and Greece (66.7%), while in
Denmark, up to three quarter of patients were treated with an anti-
arrhythmic drug. Amiodarone was generally the most widely pre-
scribed anti-arrhythmic agent across the regions studied with the
exception of Western Europe where sotalol was the most popular
anti-arrhythmic agent followed by amiodarone (Table 1). Flecainide
was the second most commonly prescribed antiarrhythmic in
Southern and Northern Europe (Figure 1); the majority of patients
prescribed flecainide across the regions had minimal or no structural
heart disease with the exception of Western Europe where the ma-
jority of patients on flecainide had hypertensive heart disease (i.e. car-
diomyopathy and hypertrophy) (19.4% vs. 1.3% in Eastern Europe
and 6.5% in Southern Europe). Generally, propafenone was not
widely prescribed across the regions except in Eastern Europe,
where it was the most common agent prescribed after amiodarone.
Dronedarone was used in only a very small proportion of patients.
Direct current cardioversion was the most common non-
pharmacological strategy used for rhythm control across the four
....................................................................................................................................................................................................................
Table 1 Use of rate and rhythm control treatments across regions
Eastern Europe Southern Europe Western Europe Northern Europe
(n5 1306) (n5 1044) (n5 325) (n5 444)
Rate control
Beta-blockers 995/1303 (76.4%) 633/1039 (60.9%) 196/325 (60.3%) 335/442 (75.8%)
Calcium channel blockers 59/1303 (4.5%) 101/1040 (9.7%) 11/325 (3.4%) 19/443 (4.3%)
Digoxin 349/1304 (26.8%) 137/1040 (13.2%) 53/325 (16.3%) 74/443 (16.7%)
Rhythm control
Dronedarone – 4/1041 (0.4%) – 5/443 (1.1%)
Flecainide 16/1303 (1.2%) 71/1041 (6.8%) 39/325 (12.0%) 27/443 (6.1%)
Propafenone 121/1304 (9.3%) 40/1041 (3.8%) 3/325 (0.9%) –
Sotalol 36/1304 (2.8%) 36/1041 (3.5%) 58/325 (17.8%) 4/444 (0.9%)
Amiodarone 355/1303 (27.2%) 190/1041 (18.3%) 52/325 (16.0%) 66/444 (14.9%)
Direct current cardioversion 172/1277 (13.5%) 230/1037 (22.2%) 116/325 (35.7%) 185/441 (42.0%)
Left atrial catheter ablation 54/1298 (4.2%) 69/1043 (6.6%) 23/325 (7.1%) 85/443 (19.2%)
Surgical AF ablation 5/1303 (0.4%) 2/365 (0.5%) – 4/443 (0.9%)
AF, atrial fibrillation.
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regions followed by left atrial catheter ablation (Table 1). Regions
with the higher proportion of direct current cardioversion also had a
proportionally higher rate of left atrial catheter ablation use. Surgical
ablation was not widely used, with only Northern Europe reporting a
rate of 0.9% (Figure 2).
Of the original cohort, 1036 (33.2%) patients were assigned to a
pure rate control management strategy whilst 355 (11.4%) were as-
signed to a pure rhythm control management strategy (Table 3). For
this analysis comparing rate vs. rhythm control strategies, all patients
that were managed with a mixed strategy (i.e. both rate and rhythm
control), or only managed with clinical observation at the baseline
were excluded. Patients assigned to rhythm control only were
younger (P< 0.0001) and less commonly female (P= 0.0266).
Patients assigned to rhythm control only strategy had a significantly
lower proportion of patients with other comorbidities, including cor-
onary artery disease (P= 0.0004), chronic heart failure (P< 0.0001),
valvular heart disease (P< 0.0001), chronic obstructive pulmonary
disease (P= 0.0048), chronic kidney disease, and peripheral vascular
disease (both P< 0.0001), when compared with the rate control
group.
The rate control group had a significantly higher proportion of pa-
tients with established cardiovascular risk factors including diabetes
(P= 0.0175), hypertension (P= 0.0060), previous ischaemic thrombo-
embolic complications (P= 0.0014), and haemorrhagic events
(P= 0.0335). Moreover, patients assigned to rate control were more
likely reported to report no physical activity (P< 0.0001). Thus, AF pa-
tients assigned to rate control had a higher CHA2DS2-VASc score
(P< 0.0001), as well as a higher proportion of patients at high
thrombo-embolic risk (CHA2DS2-VASc >_2) (P< 0.0001). Baseline
bleeding risk was higher in the rate control patients (P= 0.0003).
Patients managed with rate control strategy were more likely asymp-
tomatic compared with those assigned to rhythm control arm
(<0.0001). Patients in the rate control strategy were more likely diag-
nosed with not paroxysmal AF (P< 0.0001).
Follow-up analysis
Patients assigned to the rate control only strategy had a higher rate of
stroke/TIA compared with those assigned to rhythm control only, of
borderline significance (P= 0.0537). For any TE, the proportion in the
rate control group was two-fold that in rhythm control group
....................................................................................................................................................................................................................
Table 2 Proportion of patients with inadequate rate control according to symptomatic status across the four regions
Eastern Europe Southern Europe Western Europe Northern Europe
(n51281) (n51001) (n5 323) (n5 437)
Patients with inadequate HRa 380/1281 (29.7%) 218/1001 (21.8%) 64/323 (19.8%) 125/437 (28.6%)
EHRA I/II 146/380 (38.4%) 145/218 (66.5%) 44/64 (68.7%) 97/125 (77.6%)
EHRA III/IV 234/380 (61.6%) 73/218 (33.5%) 20/64 (31.3%) 28/125 (22.4%)
aHR <50 or >110 bpm.
Bpm, beats per minute; EHRA, European Heart Rhythm Association; HR, heart rate.
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Figure 1 Distribution of anti-arrhythmic treatments according to European regions.
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(P= 0.0245). Cardiovascular death occurrence rate was higher in the
rate control group (P= 0.0437). Similarly, all-cause death occurred
more frequently in patients assigned to rate control only strategy
than in those in rhythm control one (P< 0.0001) (Table 4).
Kaplan–Meier analysis shows that a rate control strategy was asso-
ciated with a higher risk for all-cause death (P< 0.001) (Figure 3).
When assessing survival in different geographical regions according
to management strategy, only patients from Southern Europe as-
signed to rate control had a higher risk for all-cause death (see
Supplementary material online, Figure S1) when compared with rate
control patients from other regions (P= 0.0118). No regional differ-
ence (see Supplementary material online, Figure S2) was found in
terms of mortality for rhythm control patients (P= 0.4273).
On multivariable Cox regression analysis, a rate control strategy
was independently associated with a higher risk for all-cause death
(hazard ratio: 2.83, 95% confidence interval: 1.14–7.05, P= 0.0256)
(Table 5).
Propensity score matched analysis
In order to account for comorbidities in determining the higher risk
for all-cause death, a PSM analysis was also performed (see
Supplementary material online). After the PSM, a total of 199 patients
were eligible for analysis, both for the rate control only and rhythm
control only strategies (see Supplementary material online, Table S1).
Patients assigned to rate control had more prevalent coronary artery
disease, myocardial infarction and previous revascularization proced-
ures, whilst patients assigned to rhythm control had more prevalent
stable angina. Rate control patients were more frequently smokers
and less likely to undertake physical activity. There was high
thrombo-embolic risk profile in the rate control group.
Outcome rates (see Supplementary material online, Table S2) at
follow-up were not different between the two groups after propen-
sity score matching. Cox regression analysis (see Supplementary ma
terial online, Table S3) after PSM found that age (P= 0.0467), chronic
kidney disease (P= 0.0010), and diabetes mellitus (P= 0.0055) were
independently associated with all-cause death. A rate control strategy
had a non-significant trend for higher mortality, with wide confidence
intervals [hazard ratio (HR): 3.45, 95% confidence interval (CI): 0.92–
12.97, P= 0.0664].
Discussion
This analysis of the EORP-AF pilot general registry provides us with a
‘snapshot’ of the prevailing use of rhythm and rate control therapies
throughout the four major regions in Europe, showing how fre-
quently physicians decide for either a pure rate control strategy or
rhythm control strategy. First, patients managed with rate control
only tend to be older and with more comorbidities. Secondly, among
rhythm control agents, amiodarone was the most popular drug
throughout the four European areas. Thirdly, non-pharmacological
methods of rhythm control were less frequently used compared with
direct current cardioversion. Last, a rate control strategy was associ-
ated with a higher risk for any TE, CV death, and all-cause death at
1-year follow-up. Even if rate control was associated with an
increased risk for all-cause death on Cox regression analysis, PSM
analysis did not verify those results, showing a non-significant trend
for higher risk of all-cause death, partially suggesting that an inter-
action with a worst clinical status could be considered.
Amiodarone was the most popular anti-arrhythmic pharmaco-
logical agent prescribed for rhythm control amongst the majority of
50%
40%
30%
Pa
tie
nt
s 
(%
)
20%
13.5%
4.2%
0.4%
Eastern Europe Southern Europe Western Europe Northern Europe
22.2%
6.6%
0.2%
35.7%
7.1%
0.0%
42.0%
19.2%
0.9%
10%
0%
Direct current cardioversion Left atrial catheter ablation Surgical AF ablation
Figure 2 Distribution of non-pharmacological anti-arrhythmic strategies across the European regions.
Rate vs. rhythm control and outcome in the EORP-AF registry 247
D
ow
nloaded from
 https://academ
ic.oup.com
/europace/article-abstract/20/2/243/2970041 by guest on 03 July 2020
....................................................................................................................................................................................................................
Table 3 Baseline characteristics of patients assigned to rate control and rhythm control only
Rate control Rhythm control P
n5 1036 n5 355
Demographics
Age, years median (IQR) 73.0 (65.0–79.0) 66.0 (59.0–73.0) <0.0001
Age >_75 years, n (%) 464/1036 (44.8%) 74/355 (20.8%) <0.0001
Female gender, n (%) 419/1036 (40.4%) 120/355 (33.8%) 0.0266
Concomitant disease, n (%)
Lone AF 15/1036 (1.4%) 36/355 (10.1%) <0.0001
Coronary artery disease 379/903 (42.0%) 88/290 (30.3%) 0.0004
Myocardial infarction 199/379 (52.5%) 45/88 (51.1%) 0.8167
PTCA/CABG 204/379 (53.8%) 42/88 (47.7%) 0.3020
Stable angina 121/379 (31.9%) 37/88 (42.0%) 0.0707
Chronic heart failure 554/1013 (54.7%) 77/317 (24.3%) <0.0001
NYHA III/IV 264/554 (47.7%) 26/77 (33.8%) 0.0220
Valvular heart disease 705/1008 (69.9%) 162/318 (50.9%) <0.0001
Dilated cardiomyopathy 136/1008 (13.5%) 22/317 (6.9%) 0.0017
Hypertrophic cardiomyopathy 31/1009 (3.1%) 14/317 (4.4%) 0.2490
Restrictive cardiomyopathy 6/1010 (0.6%) – 0.3455[a]
Hypertensive cardiomyopathy 191/1008 (18.9%) 51/317 (16.1%) 0.2503
Other cardiac disease 106/998 (10.6%) 19/315 (6.0%) 0.0155
Chronic obstructive pulmonary disease 146/1025 (14.2%) 30/355 (8.5%) 0.0048
Hyperthyroidism 32/1004 (3.2%) 11/352 (3.1%) 0.9543
Hypothyroidism 86/1006 (8.5%) 22/352 (6.3%) 0.1701
Chronic kidney disease 179/1035 (17.3%) 28/354 (7.9%) <0.0001
Peripheral vascular disease 153/1016 (15.1%) 22/342 (6.4%) <0.0001
Cardiovascular risk factors, n (%)
Diabetes 236/1028 (23.0%) 60/354 (16.9%) 0.0175
Hypertension 739/1033 (71.5%) 225/353 (63.7%) 0.0060
Current smoker 110/1001 (11.0%) 38/340 (11.2%) 0.9241
Hypercholesterolaemia 480/1006 (47.7%) 154/350 (44.0%) 0.2304
Alcohol >_2–3 units/day 95/964 (9.9%) 36/324 (11.1%) 0.5175
Physical activity <0.0001
None 469/970 (48.4%) 107/320 (33.4%)
Occasional 309/970 (31.9%) 103/320 (32.2%)
Regular 161/970 (16.6%) 85/320 (26.6%)
Intense 31/970 (3.2%) 25/320 (7.8%)
Comorbidities, n (%)
Ischaemic thrombo-embolic complications 164/1033 (15.9%) 32/355 (9.0%) 0.0014
Previous stroke 68/1034 (6.6%) 17/355 (4.8%) 0.2253
Previous transient ischaemic attack 64/1029 (6.2%) 9/355 (2.5%) 0.0074
Haemorrhagic events 99/1032 (9.6%) 21/355 (5.9%) 0.0335
Haemorrhagic stroke 1/99 (1.0%) 1/21 (4.8%) 0.3206[a]
Major bleeding 26/99 (26.3%) 4/21 (19.0%) 0.4880
Malignancy 53/1018 (5.2%) 25/349 (7.2%) 0.1738
Symptoms, n (%)
EHRA I 577/1036 (55.7%) 146/355 (41.1%) <0.0001
EHRA II-IV 459/1036 (44.3%) 209/355 (58.9%)
Type of AF, n (%) <0.0001
Paroxysmal AF 113/1008 (11.2%) 147/351 (41.9%)
Not paroxysmal AF 895/1008 (88.8%) 204/351 (58.1%)
CHA2DS2-VASc median (IQR) 4 (2–5) 2 (1–4) <0.0001
Thrombo-embolic Risk, n (%) <0.0001
Low risk 41/1036 (4.0%) 59/355 (16.6%)
continued
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the European regions surveyed. This finding appears to be consistent
and unchanged with the Euro Heart Survey which demonstrated that
amiodarone was the most used agent for rhythm control across the
majority of atrial fibrillation sub-types.17 The ESC guidelines generally
recommend amiodarone as first line rhythm control in with NYHA
III/IV and ‘unstable NYHA II’. From our registry data we observe a
positive trend between the prevalence of heart failure and the use of
amiodarone. Regions with higher prevalence of heart failure had a
higher proportion of amiodarone use, which is in line with current
guidelines.1 Flecainide on the other hand, is not recommended for
use in patients with chronic heart failure and coronary artery disease.
This recommendation has generally been adhered to with the major-
ity of patients prescribed flecainide across the regions having minimal
or no structural heart disease with the exception of Western Europe
where the majority of patients on flecainide had hypertensive heart
disease.
There were significant differences at baseline between the patients
treated with rate and rhythm control therapy with a general trend
for older patients with multiple comorbidities and risk factors to be
managed with a rate control therapy. This difference in baseline char-
acteristics is consistent with similar findings from previous studies
evaluating differences between rhythm and rate control.3,5 Gender
differences in rate and rhythm control use could possibly be related
to differences in symptomatic status. In a previous EORP-AF sub-
group analysis about gender differences, female patients were found
to be more likely asymptomatic than male ones.18
At present, current practice in deciding whether a patient is as-
signed to rate or rhythm control therapy is largely based on
symptoms. It is plausible that the patients who are older with more
comorbidities, such as heart failure and coronary artery disease, may
be less active in their daily life and therefore may report lower bur-
den of symptoms due to inactivity rather than good control AF symp-
toms on exercise. Our data supports this, with a higher proportion
of rate control patients in EHRA I category (i.e. no/minimal symp-
toms) compared with the rhythm control group where the majority
of patients were in EHRA II–IV category. Many antiarrhythmic drugs
are also contraindicated in AF patients with multiple comorbidities,
and given the lower burden of AF symptoms, they are more likely to
be managed with rate control therapy with beta blockers, digoxin,
and calcium channel blockers.
The causes of the differences in cardiovascular death, all-cause
death and any TE between the two groups are likely to be multifac-
torial in nature. It is difficult to precisely establish the relative contri-
butions of the successful rhythm control and established risk factors
for cardiac mortality to explain the differences in outcome data. In
terms of established cardiac risk factors, the rate control group had a
higher proportion of patients with increased risk of cardiovascular
death. Conversely, the rhythm control group had a higher proportion
of patients in the paroxysmal atrial fibrillation group, which has been
shown in multiple studies to convey a better prognosis compared
with non-paroxysmal AF groups.19,20
Multiple RCTs comparing rate and rhythm control therapies in pa-
tients with AF did not demonstrate any evidence of superiority in
terms of death or systemic embolism in either arm.3–7 Other studies
have suggested a lower mortality demonstrated in rhythm control
arms.8–10 For example, a large observational study from North
America demonstrated a lower mortality in patients with new onset
AF who were managed with a long-term rhythm control strategy.8
Other non-randomized studies with their associated confounding
factors have demonstrated fewer strokes21 and also fewer deaths8 in
patients managed with rhythm control compared with rate control
therapy.
One contemporary observational registry from North America
(ORBIT-AF) comparing rate and rhythm control therapy outcomes
found baseline differences between the two groups, which were simi-
lar to our findings.22 Patients in the rate control group were more
likely to be older with more baseline comorbidities and cardiovascu-
lar risk factors compared with the rhythm control group. Their
follow-up period was longer than EORP-AF, with a mean follow-up
of around 2 years, and an unadjusted analysis revealed that the
....................................................................................................................................................................................................................
Table 3 Continued
Rate control Rhythm control P
n5 1036 n5 355
Moderate risk 77/1036 (7.4%) 66/355 (18.6%)
High risk 918/1036 (88.6%) 230/355 (64.8%)
HAS-BLED median (IQR) 1 (1–2) 1 (0–2) <0.0001
0–2 857/1036 (82.7%) 322/355 (90.7%) 0.0003
>_3 179/1036 (17.3%) 33/355 (9.3%)
Kruskal–Wallis test is used for quantitative data. v2 or Fisher’s exact test [a] is used for binary variables.
AF, atrial fibrillation; CABG, coronary artery by-pass graft; EHRA, European Heart Rhythm Association; IQR, inter-quartile range; NYHA, New York Heart Association; PTCA,
percutaneous transluminal coronary angioplasty.
.................................................................................................
Table 4 Outcome rates at 1-year follow-up according
to baseline strategy
N (%) Rate control Rhythm control P
n5 1036 n5 355
Stroke/TIA 16/916 (1.7%) 1/338 (0.3%) 0.0537
Any TE 49/916 (5.3%) 8/338 (2.4%) 0.0245
Cardiovascular death 39/992 (3.9%) 6/355 (1.7%) 0.0437
All-cause death 102/1036 (9.8%) 9/355 (2.5%) <0.0001
TE, thrombo-embolic event; TIA, transient ischemic attack.
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rhythm control group had a significantly lower all cause death, cardio-
vascular death and also lower first stroke, embolism, and TIAs.
Similar to our analysis, these differences were non-significant be-
tween the two strategies in a fully adjusted analysis.
Large observational studies have shown that patients undergoing
AF ablation may have a significant lower risk for all-cause death23 and
stroke.23,24 Friberg and colleagues reported data from Swedish regis-
tries in 361 913 AF patients (mean follow-up: 4.4 years), and found
that AF patients that underwent catheter ablation had a consistent
lower risk for stroke [hazard ratio (HR): 0.69] and all-cause death
(HR: 0.50). This risk reduction was more pronounced in patients at
high thrombo-embolic risk and those without any AF relapse within
6 months.23 In the Intermountain AF Study, 4212 patients undergoing
AF ablation had a consistent lower thrombo-embolic risk compared
with age and sex matched AF controls without ablation.24
Inconsistency between RCTs and observational studies of rate vs.
rhythm control could be related to the strict control of comorbidities
warranted by RCTs, resulting in an overall reduction of adverse
events, beyond any specific efficacy of rate or rhythm control. In ob-
servational studies, controlling for all the possible bias would be
more difficult, and consequently, the beneficial effect with rhythm
control strategy could be related to residual confounders. Indeed, re-
sults coming from our PSM analysis showed that the higher risk found
associated with the rate control strategy is less evident when com-
paring to fully matched controls. Notwithstanding the very low num-
bers in the PSM groups, there remains a trend with the rate control
only strategy for a higher risk of all-cause death.
These differences and discrepancies in current evidence further
highlight the need for trials specifically addressing the basic issue of
whether rhythm or rate control strategy delivers superior outcomes.
Several on-going studies, such as EAST11 and the Catheter Ablation
vs. Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
(CABANA) [ClinicalTrials.gov Identifier: NCT00911508] (testing the
hypothesis that catheter ablation procedure would be superior com-
pared with standard drug therapy in reducing major outcomes) are
attempting to address this important issue.
Limitations
This study is an observational registry and this poses inherent limita-
tions by virtue of the study design, and a modest follow-up duration.
The patient recruitment has been consecutive which tends to over-
come the limitations of an observational design to a certain extent.
The countries involved in this registry were from Europe only and
the results may not be generalized to developing countries for in-
stance, where there are differences in management of AF as outlined
.................................................................................................
Table 5 Cox regression analysis for all-cause death
HR 95% CI P
Age (per year) 1.04 1.02–1.07 0.0012
Rate control (vs. rhythm control) 2.83 1.14–7.05 0.0256
Previous TIA 2.14 1.15–3.99 0.0159
Chronic heart failure 2.76 1.65–4.61 0.0001
Chronic kidney disease 2.01 1.31–3.09 0.0015
Diabetes 2.02 1.33–3.08 0.0010
Physical activity
None (ref.) – – –
Occasional 0.40 0.23–0.67 0.0005
Regular 0.29 0.11–0.72 0.0080
Intense 0.65 0.16–2.70 0.5540
CI, confidence interval; HR, hazard ratio; TIA, transient ischemic attack.
Figure 3 Kaplan–Meier curves for all-cause death according to baseline strategy.
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by previous studies.25 There was a proportion of patients lost to
follow-up (15%) which does limit the analysis to some extent but this
figure is much less than the lost to follow-up rate noted in the original
EuroHeart survey. Full details on the non-cardiovascular deaths were
also unavailable.
As this is a ‘real-world’ observational study, residual confounding
remains a possibility given the difficulties in accounting for all the po-
tential confounders in such studies that could possibly generate bias
in data analysis and interpretation, affecting the reliability of our re-
sults. Given the risks associated with rhythm control therapy,
pharmacological and non-pharmacological, the physician must care-
fully assess the patient’s medical history before choosing an appropri-
ate treatment. This choice based on medical history also likely gives
rise to the possibility of confounding by indication. We noted that
only a relatively small proportion of patients underwent ablation
(surgical and left atrial catheter) and it is therefore difficult to accur-
ately assess the impact of these therapies in this registry. Given the
small numbers after propensity score matching, the analysis could be
considered as exploratory and hypothesis generating, rather than
being definitive. Such real world data would also be no substitute for
a controlled clinical trial.
Lastly, a more contemporary approach would like to regard rate
control as a pivotal management approach, independent of whether
a rhythm control strategy approach is decided.2 Even if our method-
ology to this ancillary analysis would be considered reductionist, we
believe that our approach is more reflective of real world clinical
practice, where there is always one prevalent clinical strategy being
used.
Conclusion
In this 1-year follow-up analysis of the EORP-AF pilot general registry,
we provide data on the contemporary use of the various rate and
rhythm control therapies in four European regions. We found that in
daily clinical practice, physicians often choose a pure rate control
strategy or a pure rhythm control strategy, although these approaches
are no longer considered as being mutually exclusive. We found
some geographical variation in choice of rate vs. rhythm control as
the preferential strategy, and that a pure rate control strategy was
associated with a higher risk for adverse events at 1-year follow-up,
and partially adjusted analysis suggested that rate control independ-
ently increased the risk for all-cause death. However, a fully adjusted
PSM analysis found that this association was no longer statistically sig-
nificant, suggesting an important role of comorbidities in determining
the higher risk for all-cause death.
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